As readers of this site know well, the biomedical community here in the Commonwealth is a powerful, vibrant one that leads the way toward understanding and treating serious human disease.
Fueling the growth of this community is often academic research funding from the National Institutes of Health (NIH). This funding represents a vital component in the process that takes breakthrough discoveries from bench to bedside.
And as the debate and potential policy changes continue to swirl in Massachusetts around the country, it is imperative that health care leaders, business groups, advocates and patients collectively follow—and participate in—the health care conversation unfolding today.
In this morning’s Boston Globe, the discussion continued with a joint op-ed from Dr. Jeffrey Leiden, the chairman, president, and chief executive officer of Vertex Pharmaceuticals, and Partners’ own Dr. David Torchiana. Both executives had recently returned from a meeting of biomedical leaders at the White House, where they discussed the role of NIH funding in helping create and cultivate the next big health care breakthroughs.
Only through care, understanding, and commitment will the biomedical ecosystem we’ve helped cultivate here in Massachusetts continue to thrive and lead the way across the country and the world.